FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 359:2485-2488 December 4, 2008 Number 23 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Jamerson, K. PubMed Citation

Hypertension is one of the most important risk factors for cardiovascular and renal diseases. Currently, approximately 73 million adults in the United States and approximately 1 billion adults worldwide have hypertension, and the prevalence is increasing.¹ Many clinical trials have examined the effects of antihypertensive drugs. Studies comparing the effects of antihypertensive medications with those of placebo have shown consistently that lowering blood pressure is associated with major reductions in the incidence of coronary events, strokes, and congestive heart failure.² These benefits have been observed irrespective of age, sex, severity of the hypertension, presence or absence of associated risk factors . . . [Full Text of this Article]

Source Information

From the Department of Medicine, Boston University School of Medicine, and the Boston University Medical Center, Boston.

This article has been cited by other articles:

• Hankey, G. J. (2009). Response to Letter by Castilla-Guerra et al. Stroke 40: e76-e76 [Full Text]  
• (2008). ACE Inhibitor Plus Calcium Blocker for Hypertension. JWatch General 2008: 1-1 [Full Text]  
• (2008). Combination Therapy for Hypertension. Journal Watch Cardiology 2008: 2-2 [Full Text]